Current Partnering seeks out the best articles from various sources, to keep you updated on partnering best practice and broader topics currently being discussed and debated.
Dealmakers weekly review – January 30 2012 – Roche, Illumina, Amgen, Micromet, Celgene, Avila, Boehringer Ingelheim, Priaxon
January 31, 2012 : Big Pharma, dealtalk, financings, M&A
Three mega M&A announcements and a slowing of partnering activity more »
Top M&A 2011:over $130 billion bet on life sciences consolidation
January 30, 2012 : Big Pharma, M&A
Analysis of data from the leading deals and alliances servicer Current Agreements, shows that the top twenty M&A deals announced in the life sciences sector during 2011 had a combined value in excess of $130 billion more »
Top twenty partnering deals of 2011 have a combined value of over $21 billion
January 24, 2012 : Big Pharma, partnering, partnering agreements, partnering terms
Analysis of data from the leading deals and alliances service Current Agreements, shows that the top twenty partnering deals in the life sciences have a combined value of $21.5 billion more »
Dealmakers weekly review – January 23 2012 – Genentech, Paragon Bioservices, Neurocrine Biosciences
January 23, 2012 : Big Pharma, financings, Genentech, M&A, partnering
The start of 2012 has continued to see a surge in partnering announcements. This mirrors the level of dealmaking we saw just before the end of 2011 – where companies were wrapping up deals in time for the company year end more »
Biotech funding hits 4-year high as startups suffer
January 23, 2012 : dealtalk
Venture capital investment in biotechnology increased 22 percent last year, while the number of those receiving their first funding declined. more »
Biotech investors declare it’s never too early to plan an exit
January 17, 2012 : dealtalk, investment
It’s never too early to plan an exit strategy. Panelists at the Biotech Showcase™ 2012 luncheon plenary session Monday all agreed that, although that strategy may include an IPO, exit planning should include other strategies as well. more »
Lights are flashing green for biotech investment in China
January 17, 2012 : china
How can investors in the West take advantage of what is happening in the life science sector in China, and what are its implications for the future of US VC funding? A featured panel at Biotech Showcase™ 2012 sought some answers. more »
Dealmakers weekly review – January 16 2012 – Janssen, Boehringer, Genentech, BioReliance, Sanofi
January 17, 2012 : Big Pharma, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, M&A, partnering, partnering terms, Sanofi, Teva
The start of 2012 has seen a significant surge in partnering announcements. In addition, the JP Morgan conference in San Francisco has resulted in a rash of announcements of partnering intentions for 2012 more »
Biotech funding 2012: Innovation is not enough
January 16, 2012 : dealtalk, innovation
Written for partneringNEWS.
Venture capital is the most expensive form of capital, so companies are advised to be creative in sourcing other types of funding. With the current capital headwinds, creative alternatives may be the only options companies have, according to panelists at Biotech Showcase™ 2012’s luncheon plenary Wednesday. more »
Balancing on the innovation high wire
January 13, 2012 : innovation
Written for partneringNEWS.
Successfully managing through value inflection points for life science companies depends heavily upon their ability to manage innovation. Speakers at Tuesday’s plenary luncheon at Biotech Showcase™ 2012 spoke of the realities and substantial challenges of an environment that increasingly incorporates external and internal development programs. more »
